Oregon Health & Science University

Washington University

University of Rochester

Biorest Ltd.

Jonah Sacha

Louis Picker

Scott G Hansen

Klaus Frueh

Daniel Malouli

Jay A Nelson

Meaghan Hancock

Yoram Richter

Gershon Golomb

James J Kobie

Douglas F Nixon

Jay Nelson

CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses&#x2014;CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.

Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules

Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.

Methods and compositions useful in generating non canonical CD8+ T cell responses

The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.

Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof

Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses&#x2014;CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.

The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.

Use of bisphosphonates as HIV/AIDS adjunctive treatment

Growing community of inventors

Beaverton, OR, United States of America

Jonah Sacha